Compare FRSX & HUMAW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FRSX | HUMAW |
|---|---|---|
| Founded | N/A | 2004 |
| Country | Israel | United States |
| Employees | N/A | 220 |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.5M | N/A |
| IPO Year | 2017 | N/A |
| Metric | FRSX | HUMAW |
|---|---|---|
| Price | $1.30 | $0.09 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 615.0K | 14.2K |
| Earning Date | 03-24-2026 | 03-21-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $452,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.31 | $1.18 |
| 52 Week High | $13.22 | $1.34 |
| Indicator | FRSX | HUMAW |
|---|---|---|
| Relative Strength Index (RSI) | 22.47 | 39.50 |
| Support Level | $1.31 | $0.09 |
| Resistance Level | $1.74 | $0.12 |
| Average True Range (ATR) | 0.10 | 0.03 |
| MACD | -0.03 | 0.00 |
| Stochastic Oscillator | 0.00 | 16.99 |
Foresight Autonomous Holdings Ltd is a technology company engaged in the design, development and commercialization of vision systems for the automotive industry. The company develops both in-line-of-sight vision systems and beyond-line-of-sight cellular-based applications through its wholly-owned subsidiaries. Its systems are designed to improve driving safety by enabling accurate and reliable threat detection while ensuring the lowest rates of false alerts. Foresight is pursuing several markets and believes its modern systems will revolutionize automotive safety by providing an automotive-grade, cost-effective platform.
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.